INDV stock news · Indivior Pharmaceuticals
Get alerts for INDV
Follow Indivior Pharmaceuticals (INDV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for INDVSupernus Pharmaceuticals shares details from their earnings call for the third quarter of 2026.
Good for INDVIndivior is expected to join a merger that could strengthen earnings and cash generation. The deal has not closed, so those benefits remain expected rather than delivered.
Indivior Pharmaceuticals shared news about its merger with Supernus Pharmaceuticals and some legal issues.
NeutralIndivior updated merger disclosures after Supernus investors challenged them. Both companies deny wrongdoing and added details to limit delay risk.
Complete Transcript of Indivior's Earnings Call for Q2 2026 Released.
Good for INDVIndivior's Q2 earnings call announced a merger with Supernus Pharmaceuticals, creating a combined entity focused on CNS treatments. This merger is expected to generate significant cost synergies and enhance growth potential, making it a pivotal moment for both companies.
Q2 2026 results delivered by Supernus Pharmaceuticals: Complete earnings call transcript available.
Good for INDVIndivior Pharmaceuticals is merging with Supernus, which will enhance its portfolio and market position in CNS-focused therapies.
Don't overlook these three health care stocks this quarter that could prove to be valuable.
NeutralThe merger between Indivior Pharmaceuticals and Supernus Pharmaceuticals is expected to create a stronger entity in the CNS biopharmaceutical market, which could lead to increased investor interest and stock price appreciation for both companies.